{"analyses":[{"ciLowerLimit":"5.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.38","estimateComment":"95% Confidence Interval (CI) for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0007","pValueComment":"P-value was assessed using Cochran-Mantel-Haenszel (CMH) test stratified by the IvRS randomization stratification factors.","paramType":"Difference in Response Rates","paramValue":"13.43","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.77","upperLimit":"77.23","value":"71.3"},{"groupId":"OG001","lowerLimit":"79.22","upperLimit":"89.24","value":"84.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"OR was defined as complete response (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10\\^9/L, absence of lymphadenopathy by physical examination and computed tomography (CT) scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: two of the following features for at least 2 months: \\>/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, \\>/=50% reduction in lymphadenopathy, \\>/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles comprised 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)","title":"Percentage of Participants With an Overall Response (OR) at Completion of Treatment, as Determined by the Investigator According to IWCLL Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}